Innovent Biologics Stock Analysis
IVBXF Stock | USD 4.86 0.03 0.62% |
Innovent Biologics is overvalued with Real Value of 4.32 and Hype Value of 4.86. The main objective of Innovent Biologics pink sheet analysis is to determine its intrinsic value, which is an estimate of what Innovent Biologics is worth, separate from its market price. There are two main types of Innovent Biologics' stock analysis: fundamental analysis and technical analysis.
The Innovent Biologics pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Innovent Biologics' ongoing operational relationships across important fundamental and technical indicators.
Innovent |
Innovent Pink Sheet Analysis Notes
About 44.0% of the company shares are owned by institutional investors. The book value of Innovent Biologics was currently reported as 6.54. The company recorded a loss per share of 0.32. Innovent Biologics had not issued any dividends in recent years. Innovent Biologics, Inc. operates as a biopharmaceutical company in China. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the Peoples Republic of China. Innovent Biologics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5538 people.The quote for Innovent Biologics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Innovent Biologics call the company at 86 512 6956 6088 or check out https://www.innoventbio.com.Innovent Biologics Investment Alerts
Innovent Biologics generated a negative expected return over the last 90 days | |
Innovent Biologics has high historical volatility and very poor performance | |
Innovent Biologics has high likelihood to experience some financial distress in the next 2 years | |
The company reported the revenue of 4.27 B. Net Loss for the year was (3.14 B) with profit before overhead, payroll, taxes, and interest of 2.98 B. | |
Innovent Biologics has accumulated about 8.32 B in cash with (2.02 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Latest headline from gurufocus.com: Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating ... |
Innovent Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 8.37 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Innovent Biologics's market, we take the total number of its shares issued and multiply it by Innovent Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Innovent Profitablity
The company has Profit Margin (PM) of (0.68) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.78) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.78.Technical Drivers
As of the 14th of December 2024, Innovent Biologics retains the Risk Adjusted Performance of (0.02), market risk adjusted performance of (0.97), and Standard Deviation of 3.61. Innovent Biologics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Innovent Biologics variance and potential upside to decide if Innovent Biologics is priced fairly, providing market reflects its last-minute price of 4.86 per share. Given that Innovent Biologics has information ratio of (0.07), we strongly advise you to confirm Innovent Biologics's regular market performance to make sure the company can sustain itself at a future point.Innovent Biologics Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Innovent Biologics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Innovent Biologics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Innovent Biologics Predictive Daily Indicators
Innovent Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Innovent Biologics pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Daily Balance Of Power | 9.2 T | |||
Rate Of Daily Change | 1.01 | |||
Day Median Price | 4.86 | |||
Day Typical Price | 4.86 | |||
Price Action Indicator | 0.015 | |||
Period Momentum Indicator | 0.03 |
Innovent Biologics Forecast Models
Innovent Biologics' time-series forecasting models are one of many Innovent Biologics' pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Innovent Biologics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Innovent Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Innovent Biologics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Innovent shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Innovent Biologics. By using and applying Innovent Pink Sheet analysis, traders can create a robust methodology for identifying Innovent entry and exit points for their positions.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the Peoples Republic of China. Innovent Biologics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5538 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Innovent Biologics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Instant Ratings Now
Instant RatingsDetermine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
All Next | Launch Module |
Complementary Tools for Innovent Pink Sheet analysis
When running Innovent Biologics' price analysis, check to measure Innovent Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovent Biologics is operating at the current time. Most of Innovent Biologics' value examination focuses on studying past and present price action to predict the probability of Innovent Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovent Biologics' price. Additionally, you may evaluate how the addition of Innovent Biologics to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |